Crescent Biopharma
CBIO
27 hedge funds and large institutions have $93M invested in Crescent Biopharma in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 32 → 27 (-5)
18% less capital invested
Capital invested by funds: $114M → $93M (-$21.1M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$452K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$186K |
| 4 |
SIM
Spark Investment Management
New York
|
+$160K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.25M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$510K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$501K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$291K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$225K |
CBIO Hedge Fund Activity: Q3 2014 in Review
27 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2014, worth a combined $93M — down 18% from $114M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CBIO and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 4 added.
The largest buyer was Wellington Management Group, adding an estimated $1.59M. The largest seller was Franklin Resources, cutting an estimated $1.25M.
- 27 institutional investors held Crescent Biopharma (CBIO) as of Q3 2014, down from 32 in Q2 2014.
- Funds reported $93M of Crescent Biopharma stock for Q3 2014, down 18% quarter-over-quarter.
- 6 funds opened new Crescent Biopharma positions in Q3 2014 and 10 closed out, a net change of -4 holders.
- The largest Crescent Biopharma buyer in Q3 2014 was Wellington Management Group, an estimated $1.59M added.
- The largest Crescent Biopharma seller in Q3 2014 was Franklin Resources, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2014.